ArticleThe oncologist2026

An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer.

Justin N Malinou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.